Introduction {#s1}
============

Prostate cancer (PCa) has become a major public health problem concern worldwide for its high morbidity and mortality levels. It is the second leading cause of cancer related to death in Europe, North America, Latin America, and some parts of Africa in men. It has been reported that PCa have a prominent variation in incidence among different ethnic groups and geographic regions. For instance, North Americans have the highest incidence, especially the African-Americans in USA, and the lowest is among Asian men [@pone.0050587-Jemal1]--[@pone.0050587-Parkin1]. However, the etiology and ethnic disparities of PCa are largely unknown. Clinical and epidemiologic data suggest that the development of PCa is a multiphase process. So far, a series environmental and lifestyle factors, including pollutants, smoking habit and diet, as well as geographical and racial factors have been pointed out as possible contributors to the risk of PCa [@pone.0050587-Fleshner1]. In addition, the various risk, incidence, and mortality rates among worldwide of PCa suggest that genetic factors also play an important role in PCa initiation and progression, such as individual differences in the susceptibility to cancers, age and family history [@pone.0050587-American1]. Therefore, the occurrence and development of PCa most likely involve a complex interplay between genetic and environmental factors. More specifically, variations in carcinogen metabolism genes may play a critical role in PCa development due to their activation or detoxification functions.

10.1371/journal.pone.0050587.t001

###### Characteristics of eligible studies in the meta-analysis of *GSTM1, GSTT1* and *GSTP1* polymorphisms with PCa.
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                                                                                                *GSTM1*                                        *GSTT1*                                      *GSTP1*                                                                                                                                                                                                                                                                                                   
  ----------------------- ---------- ---------------------------------------- -------------------------------------------- ----------------------------------------------- ------------------------------------------ -------------------------------------------- ----------------------------------------------- ------------------------------------------ -------------------------------------------- ----------------------------------------------- ------------------------------------------ ---------------------------
  **Caucasians**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Harries LW                 1997                       HB                                                                                                                                                                                                                                                                                                                       10/26                                          79/76                                                                            0.440
  Rebbeck TR                 1999                       PB                                      110/126                                        110/121                                                                                   46/186                                        72/159                                                                                                                                                                                                         
  Wadelius M                 1999                       PB                                                                                                                                                                                                                                                                                                                       75/68                                          71/49                                                                            0.321
  Autrup JL                  1999                       PB                                       91/62                                         154/134                                                                                   29/124                                        44/244                                                                                    72/81                                         131/157                                                                           0.932
  Steinhoff C                2000                       HB                                       45/46                                          57/70                                                                                    23/68                                         17/110                                                                                    47/44                                          70/57                                                                            0.390
  Shepard TF                 2000                       HB                                                                                                                                                                                                                                                                                                                      290/300                                        365/438                                                                           0.893
  Gsur A                     2001                      BPH                                       75/91                                                                                       81/85                                       27/139                                                                                      33/133                                      90/57                                                                                       65/76                               0.258
  Kote-Jarai Z               2001                       PB                                      153/120                                        135/135                                                                                   67/206                                        66/212                                                                                   117/156                                        140/133                                                                           0.215
  Luscombe CJ                2002                      BPH                                                                                                                                                                                                                                                                                                                       86/123                                                                                      66/88                               0.883
  Beer TM                    2002                       PB                                       61/50                                          73/74                                                                                    28/83                                         33/113                                                                                    51/58                                          63/83                                                                            0.431
  Jeronimo C                 2002     mixed[\#](#nt102){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                     45/60                                          61/80                                                                            0.374
  Kidd LC                    2003                       /                                        84/116                                        100/88                                                                                    24/178                                        29/160                                                                                    92/78                                          95/73                                                                             NA
  Nam RK                     2003                       HB                                      235/248                                        266/282                                                                                   90/393                                        127/421                                                                                  227/256                                        286/262                                                                           0.052
  Acevedo C                  2003                      BPH                                       37/65                                                                                       29/99                                                                                                                                                                                                                                                                                                    
  Debes JD                   2004                       PB                                                                                                                                                                                                                                                                                                                      369/545                                        184/298                                                                           0.310
  Medeiros R                 2004                       PB                                       77/65                                          91/92                                                                                    31/114                                        44/140                                                                                                                                                                                                         
  Mao GE                     2004                       HB                                                                                                                                                                                                                                                                                                                       56/66                                          70/65                                                                            0.622
  Joseph MA                  2004                       PB                                       97/81                                         142/123                                                                                   55/122                                        61/204                                                                                                                                                                                                         
  Mittal RD                  2004                      BPH                                       55/48                                                                                       35/82                                       35/68                                                                                       13/104                                                                                                                                                           
  Antognelli C               2005                      BPH                                                                                                                                                                                                                                                                                                                      172/212                                                                                     220/140                              0.498
  Caceres DD                 2005                       PB                                       37/65                                         30/102                                                                                     6/94                                         14/115                                                                                                                                                                                                         
  Srivastava DSL             2005                       /                                        70/57                                          51/93                                                                                    41/86                                         29/115                                                                                    46/81                                          83/61                                                                            0.227
                                                                                              ***GSTM1***                                    ***GSTT1***                                  ***GSTP1***                                                                                                                                                                                                                                                                                                 
  **First author**         **Year**                 **Source**                 **Cases** [a](#nt101){ref-type="table-fn"}   **Controls** [a](#nt101){ref-type="table-fn"}   **BPH** [a](#nt101){ref-type="table-fn"}   **Cases** [a](#nt101){ref-type="table-fn"}   **Controls** [a](#nt101){ref-type="table-fn"}   **BPH** [a](#nt101){ref-type="table-fn"}   **Cases** [a](#nt101){ref-type="table-fn"}   **Controls** [a](#nt101){ref-type="table-fn"}   **BPH** [a](#nt101){ref-type="table-fn"}   ***P*** **value for HWE**
  Vijayalakshmi K            2005                       HB                                       18/57                                          15/85                                                                                                                                                                                                                            49/26                                          43/57                                                                            0.069
  Agalliu I                  2006                       PB                                      311/248                                        248/274                                                                                   92/466                                        88/434                                                                                   249/309                                        226/297                                                                           0.662
  Quinones LA                2006                       HB                                       22/38                                          36/81                                                                                                                                                                                                                                                                                                                                                 
  Silig Y                    2006                       HB                                       98/54                                         52/117                                                                                    34/118                                        31/138                                                                                                                                                                                                         
  Rybicki BA                 2006                       HB                                                                                                                                                                                                                                                                                                                      157/206                                         53/87                                                                            0.402
  Mittal RD                  2006                      BPH                                       31/23                                                                                       38/67                                       24/30                                                                                       30/75                                       17/37                                                                                       58/47                               0.451
  Lima MM Jr                 2008                      BPH                                       69/56                                                                                       53/47                                       42/83                                                                                       22/78                                       65/60                                                                                       55/45                               0.057
  Sivonová M                 2009                       PB                                       69/60                                         130/98                                                                                    24/105                                        45/183                                                                                    56/79                                         110/123                                                                          \<0.001
  Steinbrecher A             2010                       PB                                      126/122                                        270/221                                                                                   44/204                                        77/415                                                                                   125/123                                        216/276                                                                           0.276
  Kumar V                    2011                     HB+BPH                                     34/23                                          15/31                                        21/32                                       29/28                                          22/24                                        32/21                                                                                                                                                            
  Thakur H                   2011                     HB+BPH                                     87/63                                         62/110                                        82/68                                       39/111                                        22/150                                        18/132                                                                                                                                                           
  Rodrigues IS               2011                       PB                                       71/83                                          86/68                                                                                    42/112                                        40/114                                                                                                                                                                                                         
  Qadri Q                    2011                     PB+BPH                                                                                                                                                                                                                                                                                                                     26/24                                          59/21                                        22/23                               0.083
  Hemelrijck MV              2012                       PB                                       105/98                                        188/172                                                                                   35/168                                        64/296                                                                                   100/103                                        158/202                                                                           0.263
  **Asians**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Murata M                   2001                      BPH                                       57/58                                                                                       115/85                                      47/68                                                                                       104/96                                                                                                                                                           
  Nakazato H                 2003                       HB                                       38/43                                          53/52                                                                                    40/41                                          44/61                                                                                    57/24                                          76/29                                                                            0.101
  Aktas D                    2004                      BPH                                       19/81                                                                                       14/93                                                                                                                                                                                                                                                                                                    
  Guan TY                    2005                       PB                                       48/35                                          48/67                                                                                                                                                                                                                                                                                                                                                 
  Komiya Y                   2005                       PB                                       93/93                                         157/131                                                                                   74/112                                        139/149                                                                                   143/44                                        212/79                                                                            0.148
  Wang YL                    2005                       PB                                       44/37                                          40/50                                                                                    43/38                                          48/42                                                                                                                                                                                                         
  Lai MT                     2005                       HB                                       57/39                                          55/66                                                                                                                                                                                                                                                                                                                                                 
                                                                                              ***GSTM1***                                    ***GSTT1***                                  ***GSTP1***                                                                                                                                                                                                                                                                                                 
  **First author**         **Year**                 **Source**                 **Cases** [a](#nt101){ref-type="table-fn"}   **Controls** [a](#nt101){ref-type="table-fn"}   **BPH** [a](#nt101){ref-type="table-fn"}   **Cases** [a](#nt101){ref-type="table-fn"}   **Controls** [a](#nt101){ref-type="table-fn"}   **BPH** [a](#nt101){ref-type="table-fn"}   **Cases** [a](#nt101){ref-type="table-fn"}   **Controls** [a](#nt101){ref-type="table-fn"}   **BPH** [a](#nt101){ref-type="table-fn"}   ***P*** **value for HWE**
  Yang J                     2006                       HB                                       99/64                                         112/90                                                                                    89/74                                         95/107                                                                                                                                                                                                         
  Wang YL                    2008                       PB                                                                                                                                                                                                                                                                                                                       41/40                                          58/32                                                                            0.786
  Li M                       2008                       HB                                       121/87                                        96/134                                                                                                                                                                                                                                                                                                                                                 
  Ansari BS                  2009                       PB                                       34/26                                          25/35                                                                                    13/47                                          9/51                                                                                                                                                                                                          
  Xu XX                      2010                       PB                                                                                                                                                                                                                                                                                                                       68/35                                          70/33                                                                            0.921
  Kwon DD                    2011                       PB                                       90/76                                         125/202                                                                                   85/81                                         163/164                                                                                   117/49                                        209/118                                                                           0.300
  Ashtiani ZO                2011                     PB+BPH                                     50/60                                          10/90                                        47/52                                       38/72                                          47/53                                        37/62                                                                                                                                                            
  Safarinejad MR             2011                       PB                                       72/96                                         94/242                                                                                    58/110                                        70/266                                                                                    54/114                                        174/162                                                                          \<0.001
  **Africans**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Mallick S                  2007                       HB                                       26/108                                         36/98                                                                                    30/104                                         49/85                                                                                                                                                                                                         
  Lavander NA                2009                       PB                                       47/141                                        137/441                                                                                   36/153                                        102/482                                                                                   55/135                                        186/386                                                                           0.540
  Souiden Y                  2010                       PB                                       58/52                                          68/54                                                                                    30/80                                         18/104                                                                                                                                                                                                         
  **African-Americans**                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Agalliu I                  2006                       PB                                        9/22                                           7/8                                                                                      7/24                                          4/11                                                                                     11/20                                          1/14                                                                             0.019
  Rybicki BA                 2006                       HB                                                                                                                                                                                                                                                                                                                       82/192                                        29/104                                                                            0.120
  **Mixed**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Catsburg C                 2012                       PB                                      606/774                                        321/417                                                                                  242/1158                                       153/583                                                                                  569/843                                        300/449                                                                           0.373

Null/present.

Used both healthy people and BPH patients as controls.

*GSTM1*, glutathione S-transferase M1; *GSTT1*, glutathione S-transferase T1; *GSTP1*, glutathione S-transferase P1.

PB, population-based controls; HB, hospital-based controls; BPH, benign prostate hyperplasia.

Glutathione S-transferases (GSTs) constitute a superfamily of ubiquitous, multifunctional phase II metabolic enzymes. These enzymes play a crucial function in the detoxification of both endogenous and exogenous carcinogens [@pone.0050587-Hayes1], but also participate in the activation and inactivation of oxidative metabolites of carcinogenic compounds so that to protect DNA from oxidative damage [@pone.0050587-Ryberg1]. Hence, it has been speculated that GSTs were probably involved in the development of cancers [@pone.0050587-Rebbeck1]. As the enzymes are widely distributed in nature and found in essentially all eukaryotic species, individual genetic differences may influence the activity level of GSTs and susceptibility to cancer. To date, the GSTs have been assigned to eight distinct classes: α(*GSTA*),μ(*GSTM*),θ(*GSTT*),π(*GSTP*),σ(*GSTS*),κ(*GSTK*),ο(*GSTO*),τ(*GSTZ*), while several of them are polymorphic that contain one or more homodimer or heterodimer forms [@pone.0050587-Hayes2], [@pone.0050587-Hayes3]. Polymorphisms in these genes, possibly by altering their expression and functional activities, may affect their effect on carcinogen activation/detoxification and DNA repair.

In recent years, *GSTM1*, *GSTT1* and *GSTP1* have been studied most. The *GSTM1*, *GSTT1* and *GSTP1* gene were located on chromosome 1p13.3, 22q11.23, 11q13 respectively [@pone.0050587-Pearson1], [@pone.0050587-Webb1]. Both *GSTM1* and *GSTT1* gene exhibit an inherited homozygous deletion polymorphism (null genotype), which has been associated with the loss of enzyme activity and increased vulnerability to cytogenetic damage [@pone.0050587-Norppa1]. As a result of decreased efficiency in protection against carcinogens, the individuals with homozygous deletion polymorphism are considered to be at an increased risk for malignancies [@pone.0050587-Hayes3], [@pone.0050587-McIlwain1]. Whereas for *GSTP1* polymorphism, a single nucleotide polymorphism in exon 5 (Ile105Val, rs1695) received most attention. The A-to-G transition results in an amino acid change from isoleucine to valine so that leading to significantly lower conjugating activity among individuals who carry one or more copies of the G allele (Ile/Val or Val/Val) compared with those who have the A/A (Ile/Ile) genotype [@pone.0050587-AliOsman1]--[@pone.0050587-Sundberg1]. Recently, many studies focused on the association between PCa risk and *GSTM1*, *GSTT1* or *GSTP1* polymorphisms, but inconsistent results have been reported. In 2009, Zengnan Mo et al. conducted a meta-analysis [@pone.0050587-Mo1] suggested that *GSTM1* null genotype conferred an increasing risk of PCa on a wide population basis, but no relationship was found between *GSTT1* and *GSTP1* polymorphisms and the PCa risk. During recent three years, many new researches were performed to study the association between PCa risk and *GSTM1*, *GSTT1* or *GSTP1* polymorphisms, so an updated meta-analysis is needed.

![Flow chart of study selection.](pone.0050587.g001){#pone-0050587-g001}

![Meta-analysis of *GSTM1* null genotype and PCa risk.](pone.0050587.g002){#pone-0050587-g002}

Materials and Methods {#s2}
=====================

Search Strategy and Selection Criteria {#s2a}
--------------------------------------

According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Checklist S1), we identified all publications (updated to June 2, 2012) by conducting computer-based searches of PubMed, Embase, Google Scholar and China National Knowledge Infrastructure (CNKI). The combination of key words were as follows: 'glutathione S-transferase M1' or '*GSTM1*', 'glutathione S-transferase T1' or '*GSTT1*', 'glutathione S-transferase P1' or '*GSTP1*', 'prostate' or 'urothelial', 'cancer' or 'carcinoma' or 'neoplasm', 'polymorphism' or 'polymorphisms'. To minimize potential publication bias, no restrictions were placed on language, time period, sample size, type of study and population. All eligible articles were retrieved and their references were checked for other relevant studies. The inclusion criteria were: (1) studies which evaluated associations between *GSTM1, GSTT1, GSTP1* polymorphisms and PCa risk; (2) control population did not contain malignant tumor patients. The exclusion reasons of studies were: (1) insufficient original data for the calculation of odds ratios (ORs) with corresponding 95% confidence intervals (95%CIs); (2) when multiple reports were available for the same study population, we included only the most recent or the largest report. Two investigators independently reviewed the titles, abstracts to determine if an individual study was eligible for the inclusion and exclusion criteria and all disagreements were resolved during a consensus meeting among all reviewers.

Data Extraction {#s2b}
---------------

[Table 1](#pone-0050587-t001){ref-type="table"} summarized the following information which was extracted from all eligible studies: the name of the first author, year of publication, ethnicity, source of controls, number of cases and controls and *P*-value for Hardy Weinberg Equilibrium (HWE). To ensure the accuracy of extracted information, two independent researchers (Gong and Dong) extracted raw data according to the inclusion criteria. The conflicting evaluations were settled by a discussion among all investigators. Ethnic groups were mainly defined as Caucasian, Asian, African and African-American. Study designs were stratified into three groups: population-based studies, hospital-based studies and benign prostatic hyperplasia (BPH) based studies.

![Meta-analysis of *GSTT1* null genotype and PCa risk.](pone.0050587.g003){#pone-0050587-g003}

![Meta-analysis of *GSTP1* A131G polymorphism and PCa risk.](pone.0050587.g004){#pone-0050587-g004}

10.1371/journal.pone.0050587.t002

###### Characteristics of eligible studies in the meta-analysis for the combination of *GSTM1, GSTT1* and *GSTP1* polymorphisms with PCa.
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                                     GSTM1+GSTT1   GSTM1+GSTP1   GSTT1+GSTP1   GSTM1+GSTT1+GSTP1                                                
  ----------------- ------ -------- ------------- ------------- ------------- ------------------- --------- --------- ------- --------- ------- ---------
  **Caucasians**                                                                                                                                
  Rebbeck TR         1999     PB        22/31        468/462                                                                                    
  Autrup JL          1999     PB        19/24        153/288                                        46/92    153/288   22/24   153/288          
  Steinhoff C        2000     HB         8/4         91/127                                         20/25    91/127    10/5    91/127     1/1    91/127
  Kote-Jarai Z       2001     PB                                                                                                         21/16   269/263
  Caceres DD         2005     PB         3/5         99/129                                                                                     
  Srivastava DSL     2005     /         23/12        127/144                                        41/25    127/144   25/14   127/144   14/7    127/144
  Vijayalakshmi K    2005     HB                                                                    9/11     75/100                             
  Agalliu I          2006     PB        48/42        558/521                                       166/145   558/522   48/49   557/522          
  Lima MM Jr         2008    BPH                                    21/9            125/97                                                      
  Kumar V            2011   HB+BPH      16/8          57/46         16/12            57/53                                                      
  Thakur H           2011   HB+BPH      23/12        150/172        23/10           150/155                                                     
  **Asians**                                                                                                                                    
  Nakazato H         2003     HB                                                                                                         5/14    81/105
  Safarinejad MR     2011     PB        38/42        168/336                                        49/49    168/336   36/36   168/336   26/11   168/336
  **Africans**                                                                                                                                  
  Souiden Y          2010     PB        11/17        122/110                                                                                    

Cases/controls.

Used BPH patients as controls.

Statistical Analysis {#s2c}
--------------------

We used crude ORs with corresponding 95% CIs as a measure of the association between *GSTM1, GSTT1* and *GSTP1* polymorphisms and risk of PCa. The significance of the pooled OR was determined by the *Z* test and *P* value (two-tailed) \<0.05 was considered significant. In our study, the *I^2^* test was used to assess the heterogeneity between studies (*I^2^*\<25% no heterogeneity; *I^2^* = 25--50% moderate heterogeneity; *I^2^*\>50% large or extreme heterogeneity) [@pone.0050587-Higgins1]. The heterogeneity was considered statistically significant with *I^2^*\>50% or *P*\<0.10. When there was no heterogeneity (*I^2^*≤50% or *P*≥0.10), the fixed-effects model (the Mantel-Haenszel method) was used, otherwise, the random-effects model (the DerSimonian and Laird method) was used when the heterogeneity existed (*I^2^*\>50% or *P*\<0.10) [@pone.0050587-Mantel1], [@pone.0050587-DerSimonian1]. Subgroup analyses were performed by ethnicity, source of controls and gene-gene combinations. In addition, sensitivity analysis was performed by omitting each study in turn to assess the stability of results. To determine the evidence of publication bias, the funnel plot and Egger's test were both used. An asymmetric plot suggested possible publication bias. For the interpretation of Egger's test, statistical significance was defined as *P*\<0.05 [@pone.0050587-Egger1]. All the statistical analyses were performed with MIX statistical software (Version 1.7 for windows).

10.1371/journal.pone.0050587.t003

###### Summary of meta-analysis of *GSTM1, GSTT1* and *GSTP1* polymorphisms and PCa risk.
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  Groups                                                      No. of studies   No. of subjects        OR (95% CI)         Statistical method   *I^2^*%   *P*-value for *Z* test
  ---------------------------------------------------------- ---------------- ----------------- ------------------------ -------------------- --------- ------------------------
  **GSTM1**                                                         44              17561        1.2854(1.1405--1.4487)         Random          69.69           \<0.0001
  Caucasians                                                        26              10134        1.3028(1.1093--1.5301)         Random          72.76           \<0.0001
  Asians                                                            13              3997         1.4513(1.1682--1.803)          Random          61.46            0.0008
  Africans                                                          3               1266         0.9108(0.6943--1.1949)         Fixed             0              0.371
  hospital-based studies                                            12              3821         1.5431(1.1417--2.0856)         Random          78.24            0.0048
  population-based studies                                          23              11091        1.2192(1.0488--1.4172)         Random          68.48            0.0099
  BPH-based studies                                                 10              2307         1.3522(1.0067--1.8163)         Random          64.6             0.045
  **GSTT1**                                                         37              15948        1.102(0.9596--1.2655)          Random          65.96            0.1119
  Caucasians                                                        23              9556         1.1626(0.9712--1.3917)         Random          65.48            0.1006
  Asians                                                            9               2937         1.0533(0.8015--1.3842)         Random          65.68            0.7096
  Africans                                                          3               1273         1.0465(0.4937--2.2181)         Random          83.85            0.9057
  hospital-based studies                                            8               2814         1.1988(0.8387--1.7135)         Random          73.55            0.3199
  population-based studies                                          22              10919        1.0152(0.8789--1.1727)         Random          51.39            0.8376
  BPH-based studies                                                 8               1870         1.3345(0.8308--2.1436)         Random          79.51            0.2327
  **GSTP1**                                                         35              17644         1.0845(0.96--1.2251)          Random          69.27            0.1926
  **GSTP1** [\*](#nt108){ref-type="table-fn"}                       32              16726        1.0572(0.9391--1.1902)         Random          65.87            0.3574
  Caucasians                                                        25              12230        1.0944(0.9483--1.2629)         Random          70.19            0.2173
  Asians                                                            6               2038         1.1924(0.7953--1.7879)         Random          75.57            0.3945
  hospital-based studies                                            9               4361         0.9667(0.7548--1.238)          Random          66.95            0.7883
  population-based studies                                          18              10604        1.0675(0.9221--1.2359)         Random          62.58            0.3817
  BPH-based studies                                                 6               1874         1.2012(0.7568--1.9065)         Random          81.31            0.4367
  **GSTM1+GSTT1** [a](#nt109){ref-type="table-fn"}                  11              4550         1.4353(1.0345--1.9913)         Random          55.91            0.0306
  **GSTT1+GSTP1** [b](#nt110){ref-type="table-fn"}                  5               2493         1.7335(1.1067--2.7152)         Random          62.42            0.0163
  **GSTM1+GSTP1** [c](#nt111){ref-type="table-fn"}                  6               2689         1.3867(0.9763--1.9697)         Random          67.33            0.0679
  **Three polymorphisms** [d](#nt112){ref-type="table-fn"}          5               1711         1.6903(0.6823--4.1874)         Random          76.3             0.2568

OR, odds ratio; CI, confidence interval.

*GSTP1* the total result of after excluding three researches deviated from Hardy-Weinberg equilibrium (HWE).

*GSTM1* (−/−) and *GSTT1* (−/−) vs. *GSTM1* (+/−) and *GSTT1* (−/−) with *GSTM1* (−/−) and *GSTT1* (+/−).

*GSTT1* (−/−) and *GSTP1* (AG+GG) vs. *GSTT1* (+/−) and GSTP1 (AA) with *GSTT1* (−/−) and GSTP1 (AG+GG).

*GSTM1* (−/−) and *GSTP1* (AG+GG) vs. *GSTM1* (+/−) and GSTP1 (AA) with *GSTM1* (−/−) and GSTP1 (AG+GG).

*GSTM1* (−/−), *GSTT1* (−/−) and *GSTP1* (AG+GG) vs. the other combinations of the *GSTM1*, *GSTT1* and *GSTP1* polymorphisms.

Results {#s3}
=======

After searching with our eligibility criteria, initially a total of 94 potentially relevant publications were indentified. When screening the title or abstract, 32 studies were excluded because they are not associated with PCa risk and the polymorphisms of *GSTM1*, *GSTT1*, and *GSTP1*. Therefore, we obtained 62 relevant articles that examined the association between the polymorphisms of *GSTM1, GSTT1* or *GSTP1* and PCa risk. Out of them, three studies were excluded because of the insufficient data for OR calculation. Four researches [@pone.0050587-Murata1]--[@pone.0050587-Nock1] were eliminated because they were conducted on overlapping populations with other eligible studies [@pone.0050587-Murata2]--[@pone.0050587-Rybicki1]. Hence, 55 studies [@pone.0050587-Murata2]--[@pone.0050587-Qadri1] met our inclusion criteria and were selected in this meta-analysis. However, one of the eligible studies [@pone.0050587-Mittal2] provided data of both tissue and blood samples from the overlapping population, and we only considered the data of blood samples. In addition, two articles contained separate data on two different ethnic groups [@pone.0050587-Rybicki1], [@pone.0050587-Agalliu1], and we treated them as two separate studies. Finally, a total of 57 studies were involved in our meta-analysis ([Fig.1](#pone-0050587-g001){ref-type="fig"}). The following information was collected from each study: the name of the first author, date of publication, ethnicity, control source, number of cases and controls ([Table 1](#pone-0050587-t001){ref-type="table"}). Most of the researches contained in this meta-analysis were case-control studies, except two nested case-control studies [@pone.0050587-Steinbrecher1], [@pone.0050587-Hemelrijck1] and one cohort study [@pone.0050587-Qadri1]. Among the studies, 44 discussed the association between the *GSTM1* polymorphism and PCa risk, 37 were about *GSTT1*, and 35 were about *GSTP1*. In all eligible studies, there were 26 studies on *GSTM1* genotype of Caucasians, 13 studies of Asians, 3 studies of Africans, 1 study of African-Americans and 1 of mixed populations. Accordingly, 23 studies on *GSTT1* genotype were of Caucasians, 9 studies of Asians, 3 studies of Africans, 1 study of African-Americans and 1 of mixed populations. About *GSTP1* genotype, there were 25 studies of Caucasians, 6 studies of Asians, 2 studies of African-Americans and 1 of mixed populations. According to the control source, 26 were population-based researches, 15 were hospital-based researches, 9 studies were used BPH patients as controls, two were used both healthy people and BPH patients as controls, while the other two studies used hospital-based and BPH patients as controls. In addition, there was one study mixed the healthy people and BPH patients as controls, and the other two were not clarified.

*GSTM1* {#s3a}
-------

Data from 44 case-control studies comprising 7,893 PCa cases and 9,668 controls were pooled together for analysis of the *GSTM1* polymorphism. The overall data showed that the individuals who carried the *GSTM1* null genotype had a significantly increased PCa risk compared with those who carried the *GSTM1* present genotype in all subjects (OR = 1.2854, 95% CI = 1.1405--1.4487, *P*\<0.0001, *I^2^* = 69.69%, [Fig. 2](#pone-0050587-g002){ref-type="fig"}). Because the heterogeneity among studies was significant, the random-effects model was conducted. When stratified by ethnicity, the same dramatic risks were found in Caucasians (OR = 1.3028, 95% CI = 1.1093--1.5301, *P* = 0.0013, *I^2^* = 72.76%) and Asians (OR = 1.4513, 95% CI = 1.1682--1.803, *P* = 0.0008, *I^2^* = 61.46%). But it seems that there was no association between PCa risk and the *GSTM1* null genotype in Africans (OR = 0.9108, 95% CI = 0.6943--1.1949, *P* = 0.371, *I^2^* = 0%). When considered the source of the control groups, two studies [@pone.0050587-Kidd1], [@pone.0050587-Srivastava1] were excluded for unclear source of controls. Also, high risks were found between PCa and *GSTM1* null genotype in population-based (OR = 1.2192, 95% CI = 1.0488--1.4172, *P* = 0.0099, *I^2^* = 68.48%), hospital-based (OR = 1.5431, 95% CI = 1.1417--2.0856, *P* = 0.0048, *I^2^* = 78.24%) or in BPH-based controls (OR = 1.3522, 95% CI = 1.0067--1.8163, *P* = 0.045, *I^2^* = 64.6%).

*GSTT1* {#s3b}
-------

Totally, 37 studies met the inclusion criteria and were selected in the meta-analysis with 7,187 cases and 8,761 controls for analysis of the PCa risk and *GSTT1* null genotype. Overall, no enhanced risk was found between the null genotype of *GSTT1* polymorphism and PCa (OR = 1.102, 95% CI = 0.9596--1.2655, *P* = 0.1119, *I^2^* = 65.96%, [Fig. 3](#pone-0050587-g003){ref-type="fig"}). As the dramatic heterogeneity, the random-effects model was used. In the subgroup analysis by ethnicity, no associations were observed in Caucasians (OR = 1.1626, 95% CI = 0.9712--1.3917, *P* = 0.1006, *I^2^* = 65.48%), Asians (OR = 1.0533, 95% CI = 0.8015--1.3842, *P* = 0.7096, *I^2^* = 65.68%) or Africans (OR = 1.0465, 95% CI = 0.4937--2.2181, *P* = 0.9057, *I^2^* = 83.85%). In addition, we conducted the subgroup analysis by source of controls with omitting two researches [@pone.0050587-Kidd1], [@pone.0050587-Srivastava1] for not clarifying the source of controls. We did not found increased PCa risks with *GSTT1* null genotype in population-based (OR = 1.0152, 95% CI = 0.8789--1.1727, *P* = 0.8376, *I^2^* = 51.39%), in hospital-based (OR = 1.1988, 95% CI = 0.8387--1.7135, *P* = 0.3199, *I^2^* = 73.55%) or in BPH-based controls (OR = 1.3345, 95% CI = 0.8308--2.1436, *P* = 0.2327, *I^2^* = 79.51%).

*GSTP1* {#s3c}
-------

We obtained 35 articles after searching and data extraction based on our eligibility criteria. In total, 8,560 cases and 9,084 controls were pooled for the association between PCa risk and *GSTP1* A131G polymorphism. However, the result showed no significant risk between PCa and the *GSTP1* A131G polymorphism (OR = 1.0845, 95% CI = 0.96--1.2251, *P* = 0.1926, *I^2^* = 69.27%, [Fig. 4](#pone-0050587-g004){ref-type="fig"}). As the heterogeneity was observed, the random-effects model was used. Among the 35 studies, there were three researches deviated from HWE [@pone.0050587-Agalliu1], [@pone.0050587-Safarinejad1], [@pone.0050587-Sivonov1], so we excluded them and then obtained another result. Nevertheless, this result (OR = 1.0572, 95% CI = 0.9391--1.1902, *P* = 0.3574, *I^2^* = 65.87%) was similar with the previous one. We also performed subgroup analysis stratified by ethnicity and control source. By ethnicity, we did not acquire remarkable enhanced risks of PCa with *GSTP1* A131G polymorphism either in Caucasians (OR = 1.0944, 95% CI = 0.9483--1.2629, *P* = 0.2173, *I^2^* = 70.19%) or in Asians (OR = 1.1924, 95% CI = 0.7953--1.7879, *P* = 0.3945, *I^2^* = 75.57%). By control source, two studies [@pone.0050587-Kidd1], [@pone.0050587-Srivastava1] were eliminated as not mentioned the source of controls. The available data revealed a result that there were no enhanced PCa risks for population-based (OR = 1.0675, 95% CI = 0.9221--1.2359, *P* = 0.3817, *I^2^* = 62.58%), hospital-based (OR = 0.9667, 95% CI = 0.7548--1.238, *P* = 0.7883, *I^2^* = 66.95%) or BPH-based (OR = 1.2012, 95% CI = 0.7568--1.9065, *P* = 0.4367, *I^2^* = 81.31%) controls with the *GSTP1* A131G polymorphism.

Combination of Genotypes {#s3d}
------------------------

Several studies reported the combination of *GSTM1*, *GSTT1* and *GSTP1* genotypes ([Table 2](#pone-0050587-t002){ref-type="table"}). For the PCa patients contrast with controls, we detected the remarkable increased PCa risks for people who with dual null genotype of *GSTM1* and *GSTT1* (OR = 1.4353, 95% CI = 1.0345--1.9913, *P* = 0.0306, *I^2^* = 55.91%) and people who with *GSTT1* null genotype and *GSTP1* A131G polymorphism (OR = 1.7335, 95% CI = 1.1067--2.7152, *P* = 0.0163, *I^2^* = 62.42%). However, when combined the *GSTM1* null genotype and *GSTP1* A131G polymorphism (OR = 1.3867, 95% CI = 0.9763--1.9697, *P* = 0.0679, *I^2^* = 67.33%), or the three genotypes (OR = 1.6903, 95% CI = 0.6823--4.1874, *P* = 0.2568, *I^2^* = 76.3%), no dramatic PCa risks were obtained.

Sensitivity Analyses {#s3e}
--------------------

Sensitivity analyses were performed by sequential omission of individual studies for all subjects and subgroups. The corresponding pooled ORs were not materially altered in all subjects and subgroups of *GSTM1*, *GSTT1* or *GSTP1* genotypes (data not shown). The results of sensitivity analyses indicated the stability of the results of this meta-analysis.

Publication Bias {#s3f}
----------------

Funnel plot and Egger's test were both performed to access the publication bias in this meta-analysis. The funnel plot shapes of *GSTM1* and *GSTP1* polymorphisms were symmetrical (data not shown) and the *P* values of Egger's test were 0.0625 and 0.4738 respectively, so the results showed no evidence of publication biases. However, the shape of *GSTT1* genotype revealed a little unsymmetrical (data not shown), therefore the Egger's test was further applied to provide statistical evidence and the result suggested the publication bias might be existed, and the *P* value was 0.0415. Hence, we conducted the trim-and-fill in order to get further information. The result revealed that the number of imputed studies was zero, and also the corrected OR was 1.102 (95% CI = 0.9596--1.2655) which was the same as the uncorrected one.

Discussion {#s4}
==========

PCa is the most commonly diagnosed non-skin malignancy among men and its incidence is expected to increase as the population age elevated [@pone.0050587-Foley1]. The molecular genetics of PCa is poorly understood. Its heterogeneous nature suggests that predisposition to PCa may involve multiple genes and variable phenotypic expression. The glutathiones S-transferases (GSTs) are the most important parts of phase II superfamily of metabolism enzymes. In humans, there are several GST classes that are encoded by distinct gene families [@pone.0050587-Strange1]. Among them, *GSTM1*, *GSTT1* and *GSTP1* should be pointed out because the polymorphisms of these genes may influence the enzyme activity, and eventually increase vulnerability to genotoxic damage [@pone.0050587-McIlwain1]. Therefore, the association between the polymorphisms of *GSTM1*, *GSTT1* or *GSTP1* and PCa has been intensively investigated.

In this study, association between *GSTM1, GSTT1* or *GSTP1* genetic variants and PCa risk were examined and all the results of the present meta-analysis were summarized in [Table 3](#pone-0050587-t003){ref-type="table"}. Our result suggested that a significant increased risk existed between PCa and *GSTM1* null genotype, whereas no elevated PCa risks were observed with the *GSTT1* null genotype and *GSTP1* polymorphism. It is consistent with the result of former meta-analysis, which was conducted by Zengnan Mo et al. in 2009. However, we included 11313 cases and 12934 controls from 57 studies in the present meta-analysis, which is much more than the previous one including 7,984 cases and 9,143 controls from 39 case-control studies. Hence, a more stringent and comprehensive result has been obtained.

It is known that the allele frequencies of metabolic genes are not equally distributed throughout the human population but follow diverse ethnic patterns, therefore, the subgroups according to ethnicity were performed. Our results indicated that significant PCa risks of people with *GSTM1* null genotype are in all subjects, especially in Caucasians and Asians, but not in Africans. The possible reason of the conflicting results among diverse ethnicities could be that different genetic backgrounds and environment they exposed to may have different effects on the PCa risk. Additionally, as limited sample size may have not enough statistical power to detect a real effect or generate a fluctuated estimation, the small sample size of Africans in this meta-analysis should also be taken into consideration.

Furthermore, we also showed that *GSTM1* null genotype has strikingly increased the risk of PCa susceptibility when stratified by control source. However, we obtained the highest risk of PCa when only considered the hospital-based controls. The possible reason may be that *GSTM1* null genotype could influence the susceptibility to non-cancer diseases, such as COPD [@pone.0050587-Xue1], alcoholic liver disease [@pone.0050587-Marcos1], and coronary heart disease [@pone.0050587-Wang3], so its genotype frequency possibly differed between the hospital-based and population-based controls. Besides, we got a higher PCa risk of BPH-based controls than population controls. For this result, the probably reason could be the selection bias. To be specific, the differences of selection criteria or selection chance between population and BPH-based controls may be the main reasons of the selection bias. On the other hand, we did not exclude that the BPH could be affected by the *GSMT1* null genotype [@pone.0050587-Choubey1] was one of the reasons for the result. However, the exactly reason need to be further confirmed.

In addition, we first observed the association between the combination of *GSTM1, GSTT1* or *GSTP1* genotypes and PCa risk and revealed important results. Eleven articles examined the people with dual null genotype of *GSTM1* and *GSTT1*, and our result proved a remarkable increased PCa risk for these people. Moreover, the result also revealed a very strong risk of PCa for people who with *GSTT1* null genotype and *GSTP1* A131G polymorphism from five articles. The present meta-analysis is the earliest one to evaluate the potential interaction of the gene-to-gene and PCa risk. However, we should treat the results with caution for the limited sample size.

For the *GSTT1* null genotype and *GSTP1* A131G polymorphism, we failed to find the association between PCa risk and the polymorphisms, even though we stratified for ethnicity and control source, which is consistent with the previous meta-analysis [@pone.0050587-Mo1].

However, there are some limitations in this meta-analysis. First of all, even though we performed subgroup analyses stratified by ethnicity and control source, the heterogeneity for *GSTM1* polymorphism among the studies was extreme. It suggested that there were other potential confounding factors in the included studies, such as the genotyping error, selection bias, or population-specific gene-gene or gene-environment interaction, allelic heterogeneity, or chance [@pone.0050587-Zintzaras1], [@pone.0050587-Lin1]. Although evidence of heterogeneity exists, it was found through sensitivity analysis that studies contribute to the heterogeneity do not significantly alter the estimate of overall odds ratio. Secondly, only published studies were included, therefore the publication bias may have been occurred. The Egger's test provided statistical evidence of that. We observed the publication bias when only considered studies about the association between *GSTT1* polymorphism and PCa risk, but did not find it in the studies about the PCa risks with *GSTM1* and *GSTP1* polymorphisms. It is known that positive results usually have a greater probability of being published, and such bias may occur when studies with null or unexpected results. In addition, we also performed the trim-and-fill and the corrected OR was the same as the uncorrected one. Therefore, our result of *GSTT1* null genotype was reliable and stable to some extent. Thirdly, the overall outcomes were based on unadjusted effect estimates. Although the cases and controls were matched on age, sex and residence in all studies, these confounding factors might slightly modify the effective estimates and a more precise evaluation needed to be adjusted by the potentially suspected factors. Finally, as the meta-analysis remains a retrospective research which is subject to the methodological deficiencies of the included studies, we tried to develop a detailed protocol before initiating the study, and then performed an explicit method for study researching, selection, data extraction and data analysis to minimize the likelihood of bias.

Conclusions {#s4a}
-----------

In conclusion, our meta-analysis suggested that *GSTM1* null genotype is associated with a high increased risk of PCa and no significant PCa risks were obtained for *GSTT1* and *GSTP1* polymorphisms. To our knowledge, the present study is the first meta-analysis to date to report the interaction between the combination of *GSTM1, GSTT1* or *GSTP1* genotypes and PCa risk. In the meta-analysis, we proved remarkable elevated PCa risks for people who with dual null genotype of *GSTM1* and *GSTT1,* and also for people who with *GSTT1* null genotype and *GSTP1* A131G polymorphism. Larger and more rigorous analytical studies will be required to confirm our findings and evaluate gene-environment interactions with PCa risk.
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